You are here

P&T July 2015

Features

The FDA and Congress Are Expanding Public Access to Data

Years of complaints about poor access to information on “compassionate use” of experimental drugs and a lack of transparency in clinical trials are driving reform efforts by the National Library of Medicine, the Food and Drug Administration, and Congress.

Many studies have evaluated the role of vasopressors and inotropes in the management of septic shock. This review assesses evidence for the use of specific vasopressors, adjunctive vasopressor therapy, and inotropic agents for myocardial dysfunction.

Sodium-glucose linked transporter 2 inhibitors limit the reabsorption of glucose from glomerular filtrate in the kidneys, reducing blood glucose levels in patients with type- 2 diabetes. This article is meant to evaluate this class of medications for clinicians.

Meeting Highlights

We review key sessions on pharmacological treatment, including four on irritable bowel syndrome and others on pancreatitis and Helicobacter pylori infection.

Pipeline Plus

Life-threatening sepsis presents with varying symptoms due to the wide range of pathogens that cause it, and sepsis-specific treatment options for patients are sparse.

Departments

Medication Errors

Safety strategies for avoiding tragedies with Lugol’s solution

Letter to the Editor
Prescription: Washington

FDA may step up enforcement for homeopathic products.

FDA approvals, drug indications, and updates

Deoxycholic acid (Kybella) for submental fat; codeine polistirex/chlorpheniramine polistirex extended-release (Tuzistra XR) for coughs, allergies, and colds; ramucirumab (Cyramza) for colorectal cancer; and fluticasone furoate/vilanterol (Breo Ellipta) for asthma

Drug Forecast

Ramucirumab (Cyramza): A breakthrough treatment for gastric cancer